Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium

Inclusion Criteria

• Individuals 40 years and above, with a seated blood pressure > 130/80 mm Hg on two consecutive readings (or BP > 120/80 mm Hg in patients under treatment with 2 or more antihypertensive medication) with one of the following
• Coronary artery disease; previous myocardial infarction (>7 days post uncomplicated MI), or
• Ischemic heart disease with significant ECG changes or a positive stress test, or
• Stable angina or unstable angina and with documented evidence of multi-vessel (angiography or ECG or CT angiography) coronary artery disease, or
• PTCA or CABG Surgery >30 days before informed consent.
• Cerebrovascular disease; Previous Ischemic stroke or Transient Ischemic Attacks >30 days before informed consent.
• High risk diabetes mellitus defined as HbA1C >7.5%, with microalbuminuria or blood pressure >140/90 mm Hg.
• Peripheral artery disease defined as a current or prior history of: physician diagnosed intermittent claudication or vascular surgery for atherosclerotic disease or an ankle/arm systolic blood pressure ratio ≤ 0.90 in either leg at rest, or angiographic or doppler study demonstrating ≥ 70% stenosis in a noncardiac artery.
• Those who provide informed consent and can comply with medications and follow-up visits.

Exclusion Criteria

• Known hypersensitivity or intolerance to any of the study medications or a clear indication for full doses of beta blockers, RAAS blockers (ACEi, ARBs, Renin inhibitors, etc.), diuretics and statins.
• History of bleeding or having hemorrhagic stroke anytime in the past or a need for continued anticoagulation therapy.
• Patients having indication for higher doses of aspirin or needing more than 75mg of clopidogrel daily.
• Have significant bradycardia (heart rate 2 mg/dL and/or serum potassium >5.0 mEq/L.
• Patients aged >70 years, with mild renal dysfunction defined as serum creatinine >124 µmol/L (1.4 mg/dL) or eGFR 3 x ULN.
• Taking another experimental drug or within 30days of last dose of the experimental drug.
• Peptic ulcer disease with bleed, or bleeding diathesis.
• Bronchial asthma or Chronic Obstructive Pulmonary Disease with asthma.
• Gout, rheumatoid arthritis or other chronic inflammatory disease requiring long-term medications with NSAIDs.
• Any history of muscular pain, other pathology of the muscles or past history of muscular pain secondary to taking statins or fibrates.
• Pregnancy or lactating or women of childbearing potential with inadequate contraception.
• Inability to attend follow up visits (due to significant disability, inadequate address or contact details, subject from a far off place, psychiatric illness etc.).